Literature DB >> 27909142

Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis.

Kristina Juneblad1,2, Solbritt Rantapää-Dahlqvist3,4, Gerd-Marie Alenius3,4.   

Abstract

OBJECTIVE: Recent studies indicate increased cardiovascular (CV) morbidity and mortality in patients with psoriatic arthritis (PsA), but results are inconsistent. This prompted our investigation of the mortality rate, cause of death, and incidence of acute CV events in patients from northern Sweden with PsA.
METHODS: Patients with established PsA (464) were included. To calculate standardized mortality ratio (SMR) and standardized incidence ratio (SIR) for CV events, data were extracted from the National Causes of Death Register and the National Inpatient Care Register in Sweden, and compared with the general population. The study period was 1995-2011. To study the effect of inflammatory activity, a composite disease activity index (DAI) was used.
RESULTS: The SMR (95% CI) for overall mortality and diseases of the circulatory system (International Classification of Diseases, 10th edition; I00-I99) was 1.22 (0.89-1.63) and 1.64 (1.02-2.52), respectively. In regression analysis, DAI was significantly associated with death (OR 1.99, 95% CI 1.41-2.80) when adjusted for age and sex (p < 0.001), and remained significant after stratifying patients into the 2 major causes of death: diseases of the circulatory system and malignant neoplasms. Peripheral and axial disease was associated with death (OR 4.02, 95% CI 1.84-8.84, p < 0.001) compared with peripheral disease only. The SIR (95% CI) for a CV event (myocardial infarction or stroke) was 0.597 (0.40-0.86); this association was only significant in men.
CONCLUSION: Patients with PsA had a small but significant increase in SMR for death due to diseases of the circulatory system compared with the general population. Among patients, death was associated with DAI, as well as axial involvement in combination with peripheral disease, indicating more aggressive disease phenotypes.

Entities:  

Keywords:  CARDIOVASCULAR DISEASES; DISEASE ACTIVITY; EPIDEMIOLOGY; MORTALITY; PSORIATIC ARTHRITIS

Mesh:

Year:  2016        PMID: 27909142     DOI: 10.3899/jrheum.160070

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease.

Authors:  Zhoulan Zheng; Qianyu Guo; Dan Ma; Xuexue Wang; Chengqiang Zhang; Haiyao Wang; Liyun Zhang; Gailian Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-06

2.  Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Authors:  Karen M Fagerli; Lianne Kearsley-Fleet; Louise K Mercer; Kath Watson; Jon Packham; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

3.  Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.

Authors:  Dafna D Gladman; Christina Charles-Schoeman; Iain B McInnes; Douglas J Veale; Bruce Thiers; Mike Nurmohamed; Dani Graham; Cunshan Wang; Thomas Jones; Robert Wolk; Ryan DeMasi
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-10       Impact factor: 4.794

4.  Mortality in Inflammatory Rheumatic Diseases: Lithuanian National Registry Data and Systematic Review.

Authors:  Jolanta Dadonienė; Greta Charukevič; Gabija Jasionytė; Karolina Staškuvienė; Dalia Miltinienė
Journal:  Int J Environ Res Public Health       Date:  2021-11-24       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.